Koselugo

Chemical Nameselumetinib
Dosage FormCapsules (oral; 10 mg, 25 mg)
Drug ClassKinase inhibitors
SystemNervous
CompanyAstraZeneca
Approval Year2020

Indication

  • Indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).
Last updated on 12/8/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Koselugo (selumetinib) Prescribing Information.2020AstraZeneca Pharmaceuticals LP, Wilmington, DE